366 related articles for article (PubMed ID: 19795170)
21. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.
Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U
Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994
[TBL] [Abstract][Full Text] [Related]
22. The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.
John T; Starmans MH; Chen YT; Russell PA; Barnett SA; White SC; Mitchell PL; Walkiewicz M; Azad A; Lambin P; Tsao MS; Deb S; Altorki N; Wright G; Knight S; Boutros PC; Cebon JS
PLoS One; 2013; 8(7):e67876. PubMed ID: 23935846
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of expression of cancer/testis antigen and down-regulation of HLA class-I in patients with stage I non-small cell lung cancer.
Hanagiri T; Shigematsu Y; Shinohara S; Takenaka M; Oka S; Chikaishi Y; Nagata Y; Baba T; Uramoto H; So T; Yamada S
Anticancer Res; 2013 May; 33(5):2123-8. PubMed ID: 23645764
[TBL] [Abstract][Full Text] [Related]
24. MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma.
Bujas T; Marusic Z; Peric Balja M; Mijic A; Kruslin B; Tomas D
Eur J Histochem; 2011 Mar; 55(1):e7. PubMed ID: 21556122
[TBL] [Abstract][Full Text] [Related]
25. Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.
Luetkens T; Kobold S; Cao Y; Ristic M; Schilling G; Tams S; Bartels BM; Templin J; Bartels K; Hildebrandt Y; Yousef S; Marx A; Haag F; Bokemeyer C; Kröger N; Atanackovic D
Cancer Immunol Immunother; 2014 Nov; 63(11):1151-62. PubMed ID: 25078248
[TBL] [Abstract][Full Text] [Related]
26. Cancer immunotherapy using artificial adjuvant vector cells to deliver NY-ESO-1 antigen to dendritic cells in situ.
Fujii SI; Yamasaki S; Hanada K; Ueda S; Kawamura M; Shimizu K
Cancer Sci; 2022 Mar; 113(3):864-874. PubMed ID: 34971473
[TBL] [Abstract][Full Text] [Related]
27. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
[TBL] [Abstract][Full Text] [Related]
28. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: retrospective immunohistochemical study.
Matković B; Juretić A; Spagnoli GC; Separović V; Gamulin M; Separović R; Sarić N; Basić-Koretić M; Novosel I; Kruslin B
Croat Med J; 2011 Apr; 52(2):171-7. PubMed ID: 21495200
[TBL] [Abstract][Full Text] [Related]
29. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Tessari A; Pilla L; Silvia D; Duca M; Paolini B; Carcangiu ML; Mariani L; de Braud FG; Cresta S
Breast; 2018 Dec; 42():68-73. PubMed ID: 30189381
[TBL] [Abstract][Full Text] [Related]
30. Possible predictive role of cancer/testis antigens in breast ductal carcinoma
Roguljic A; Spagnoli G; Juretic A; Sarcevic B; Banovic M; Beketic Oreskovic L
Oncol Lett; 2018 Dec; 16(6):7245-7255. PubMed ID: 30546463
[TBL] [Abstract][Full Text] [Related]
31. Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck.
Veit JA; Heine D; Thierauf J; Lennerz J; Shetty S; Schuler PJ; Whiteside T; Beutner D; Meyer M; Grünewald I; Ritter G; Gnjatic S; Sikora AG; Hoffmann TK; Laban S
Head Neck; 2016 Jul; 38(7):1008-16. PubMed ID: 26874246
[TBL] [Abstract][Full Text] [Related]
32. Expression of MAGE-A and NY-ESO-1 cancer/testis antigens is enriched in triple-negative invasive breast cancers.
Raghavendra A; Kalita-de Croft P; Vargas AC; Smart CE; Simpson PT; Saunus JM; Lakhani SR
Histopathology; 2018 Jul; 73(1):68-80. PubMed ID: 29465777
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological assessment of cancer/testis antigens NY‑ESO‑1 and MAGE‑A4 in osteosarcoma.
Hashimoto K; Nishimura S; Ito T; Oka N; Kakinoki R; Akagi M
Eur J Histochem; 2022 Jun; 66(3):. PubMed ID: 35736245
[TBL] [Abstract][Full Text] [Related]
34. [Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide].
Liu JW; Lu X; Yang ZM; Deng LJ; Yang L
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):840-846. PubMed ID: 29045966
[TBL] [Abstract][Full Text] [Related]
35. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
Ishihara M; Kageyama S; Miyahara Y; Ishikawa T; Ueda S; Soga N; Naota H; Mukai K; Harada N; Ikeda H; Shiku H
BMC Cancer; 2020 Jun; 20(1):606. PubMed ID: 32600281
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
Krishnadas DK; Shusterman S; Bai F; Diller L; Sullivan JE; Cheerva AC; George RE; Lucas KG
Cancer Immunol Immunother; 2015 Oct; 64(10):1251-60. PubMed ID: 26105625
[TBL] [Abstract][Full Text] [Related]
37. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
[TBL] [Abstract][Full Text] [Related]
38. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.
Bolli M; Schultz-Thater E; Zajac P; Guller U; Feder C; Sanguedolce F; Carafa V; Terracciano L; Hudolin T; Spagnoli GC; Tornillo L
Int J Cancer; 2005 Jul; 115(6):960-6. PubMed ID: 15751033
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: Implications for immunotherapy.
Akcakanat A; Kanda T; Tanabe T; Komukai S; Yajima K; Nakagawa S; Ohashi M; Hatakeyama K
Int J Cancer; 2006 Jan; 118(1):123-8. PubMed ID: 16003736
[TBL] [Abstract][Full Text] [Related]
40. Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine-2,3-dioxygenase in microenvironment of nonsmall cell lung cancer.
Wang H; Xia Y; Yu J; Guan H; Wu Z; Ban D; Wang M
HLA; 2019 Jul; 94(1):39-48. PubMed ID: 30953385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
